Original article: Application of physiologically based pharmacokinetic modeling to predict acetaminophen metabolism and pharmacokinetics in children

CPT: Pharmacometrics and Systems Pharmacology

Volumn 2, Issue 10, 2013, Pages

  Jiang, X L ^a   Zhao, P ^b   Barrett, J S ^c   Lesko, L J ^a   Schmidt, S ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PARACETAMOL;

ADOLESCENT; CHILD; COMPUTER MODEL; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG EXCRETION; DRUG EXPOSURE; DRUG METABOLISM; HUMAN; HUMAN EXPERIMENT; IN VITRO STUDY; IN VIVO STUDY; INFANT; NEWBORN; PRESCHOOL CHILD; PRIORITY JOURNAL; REVIEW; SCHOOL CHILD;

EID: 84891823519     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1038/psp.2013.55     Document Type: Review

References (49)

1. Weil, K. et al. Paracetamol for pain relief after surgical removal of lower wisdom teeth. Cochrane Database Syst. Rev. CD004487 (2007).
2. Kearns, G.L., Abdel-Rahman, S.M., Alander, S.W., Blowey, D.L., Leeder, J.S. & Kauffman, R.E. Developmental pharmacology-drug disposition, action, and therapy in infants and children. N. Engl. J. Med. 349, 1157-1167 (2003). (Pubitemid 37122329)
3. Hines, R.N. Developmental expression of drug metabolizing enzymes: impact on disposition in neonates and young children. Int. J. Pharm. 452, 3-7 (2013).
4. Ji, P. et al. Regulatory review of acetaminophen clinical pharmacology in young pediatric patients. J. Pharm. Sci. 101, 4383-4389 (2012).
5. Hopkins, C.S., Underhill, S. & Booker, P.D. Pharmacokinetics of paracetamol after cardiac surgery. Arch. Dis. Child. 65, 971-976 (1990). (Pubitemid 20304937)
6. Zhao, L. & Pickering, G. Paracetamol metabolism and related genetic differences. Drug Metab. Rev. 43, 41-52 (2011).
7. Bárzaga Arencibia, Z. & Choonara, I. Balancing the risks and benefits of the use of over-the-counter pain medications in children. Drug Saf. 35, 1119-1125 (2012).
8. FDA. FDA Drug Safety Communication: Prescription Acetaminophen Products to be Limited to 325 mg Per Dosage Unit; Boxed Warning Will Highlight Potential for Severe Liver Failure. (2011). Accessed 16 July 2013.
9. Zuppa, A.F. et al. Safety and population pharmacokinetic analysis of intravenous acetaminophen in neonates, infants, children, and adolescents with pain or Fever. J. Pediatr. Pharmacol. Ther. 16, 246-261 (2011).
10. Le Vaillant, J., Pellerin, L., Brouard, J. & Eckart, P. [Acetaminophen (paracetamol) causing renal failure: report on 3 pediatric cases]. Arch. Pediatr. 20, 650-653 (2013).
11. Levy, G., Khanna, N.N., Soda, D.M., Tsuzuki, O. & Stern, L. Pharmacokinetics of acetaminophen in the human neonate: formation of acetaminophen glucuronide and sulfate in relation to plasma bilirubin concentration and D-glucaric acid excretion. Pediatrics 55, 818-825 (1975).
12. Miyagi, S.J. & Collier, A.C. The development of UDP- glucuronosyltransferases 1A1 and 1A6 in the pediatric liver. Drug Metab. Dispos. 39, 912-919 (2011).
13. Miyagi, S.J., Milne, A.M., Coughtrie, M.W. & Collier, A.C. Neonatal development of hepatic UGT1A9: implications of pediatric pharmacokinetics. Drug Metab. Dispos. 40, 1321-1327 (2012).
14. Miyagi, S.J. & Collier, A.C. Pediatric development of glucuronidation: the ontogeny of hepatic UGT1A4. Drug Metab. Dispos. 35, 1587-1592 (2007). (Pubitemid 47296052)
15. Zaya, M.J., Hines, R.N. & Stevens, J.C. Epirubicin glucuronidation and UGT2B7 developmental expression. Drug Metab. Dispos. 34, 2097-2101 (2006). (Pubitemid 44837771)
16. Hines, R.N. Ontogeny of human hepatic cytochromes P450. J. Biochem. Mol. Toxicol. 21, 169-175 (2007). (Pubitemid 350194376)
17. Johnsrud, E.K., Koukouritaki, S.B., Divakaran, K., Brunengraber, L.L., Hines, R.N. & McCarver, D.G. Human hepatic CYP2E1 expression during development. J. Pharmacol. Exp. Ther. 307, 402-407 (2003). (Pubitemid 37151933)
18. Danhof, M., de Jongh, J., De Lange, E.C., Della Pasqua, O., Ploeger, B.A. & Voskuyl, R.A. Mechanism-based pharmacokinetic-pharmacodynamic modeling: biophase distribution, receptor theory, and dynamical systems analysis. Annu. Rev. Pharmacol. Toxicol. 47, 357-400 (2007).
19. Johnson, T.N. & Rostami-Hodjegan, A. Resurgence in the use of physiologically based pharmacokinetic models in pediatric clinical pharmacology: parallel shift in incorporating the knowledge of biological elements and increased applicability to drug development and clinical practice. Paediatr. Anaesth. 21, 291-301 (2011).
20. de Morais, S.M., Uetrecht, J.P. & Wells, P.G. Decreased glucuronidation and increased bioactivation of acetaminophen in Gilbert's syndrome. Gastroenterology 102, 577-586 (1992).
21. Navarro, S.L. et al. UGT1A6 and UGT2B15 polymorphisms and acetaminophen conjugation in response to a randomized, controlled diet of select fruits and vegetables. Drug Metab. Dispos. 39, 1650-1657 (2011).
22. Allegaert, K., Naulaers, G., Vanhaesebrouck, S. & Anderson, B.J. The paracetamol concentration-effect relation in neonates. Paediatr. Anaesth. 23, 45-50 (2013).
23. Edginton, A.N., Schmitt, W. & Willmann, S. Development and evaluation of a generic physiologically based pharmacokinetic model for children. Clin. Pharmacokinet. 45, 1013-1034 (2006). (Pubitemid 44436004)
24. FDA. FDA Safety and Innovation Act. (2012). Accessed 16 July 2013.
25. Zisowsky, J., Krause, A. & Dingemanse, J. Drug development for pediatric populations: regulatory aspects. Pharmaceutics 2, 364-388 (2010).
26. Leong, R. et al. Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials. Clin. Pharmacol. Ther. 91, 926-931 (2012).
27. Barrett, J.S., Della Casa Alberighi, O., Läer, S. & Meibohm, B. Physiologically based pharmacokinetic (PBPK) modeling in children. Clin. Pharmacol. Ther. 92, 40-49 (2012).
28. Abdel-Rahman, S.M., Amidon, G.L., Kaul, A., Lukacova, V., Vinks, A.A. & Knipp, G.T.; Members of the BCS Task Force. Summary of the National Institute of Child Health and Human Development-best pharmaceuticals for Children Act Pediatric Formulation Initiatives Workshop-Pediatric Biopharmaceutics Classification System Working Group. Clin. Ther. 34, S11-S24 (2012).
29. Einolf, H.J. Comparison of different approaches to predict metabolic drug-drug interactions. Xenobiotica. 37, 1257-1294 (2007). (Pubitemid 350035530)
30. Strougo, A., Eissing, T., Yassen, A., Willmann, S., Danhof, M. & Freijer, J. First dose in children: physiological insights into pharmacokinetic scaling approaches and their implications in paediatric drug development. J. Pharmacokinet. Pharmacodyn. 39, 195-203 (2012).
31. Edginton, A.N. Knowledge-driven approaches for the guidance of first-in-children dosing. Paediatr. Anaesth. 21, 206-213 (2011).
32. Court, M.H. et al. Interindividual variability in acetaminophen glucuronidation by human liver microsomes: identification of relevant acetaminophen UDP-glucuronosyltransferase isoforms. J. Pharmacol. Exp. Ther. 299, 998-1006 (2001). (Pubitemid 33104971)
33. Miners, J.O., Bowalgaha, K., Elliot, D.J., Baranczewski, P. & Knights, K.M. Characterization of niflumic acid as a selective inhibitor of human liver microsomal UDPglucuronosyltransferase 1A9: application to the reaction phenotyping of acetaminophen glucuronidation. Drug Metab. Dispos. 39, 644-652 (2011).
34. Miller, R.P., Roberts, R.J. & Fischer, L.J. Acetaminophen elimination kinetics in neonates, children, and adults. Clin. Pharmacol. Ther. 19, 284-294 (1976).
35. Court, M.H., Zhang, X., Ding, X., Yee, K.K., Hesse, L.M. & Finel, M. Quantitative distribution of mRNAs encoding the 19 human UDP- glucuronosyltransferase enzymes in 26 adult and 3 fetal tissues. Xenobiotica. 42, 266-277 (2012).
36. Ekström, L., Johansson, M. & Rane, A. Tissue distribution and relative gene expression of UDP-glucuronosyltransferases (2B7, 2B15, 2B17) in the human fetus. Drug Metab. Dispos. 41, 291-295 (2013).
37. Zunino, F., Pratesi, G., Micheloni, A., Cavalletti, E., Sala, F. & Tofanetti, O. Protective effect of reduced glutathione against cisplatin-induced renal and systemic toxicity and its influence on the therapeutic activity of the antitumor drug. Chem. Biol. Interact. 70, 89-101 (1989). (Pubitemid 19161217)
38. Gallagher, E.P. & Sheehy, K.M. Effects of phenytoin on glutathione status and oxidative stress biomarker gene mRNA levels in cultured precision human liver slices. Toxicol. Sci. 59, 118-126 (2001). (Pubitemid 32117988)
39. Poulin, P. & Theil, F.P. Prediction of pharmacokinetics prior to in vivo studies. 1. Mechanismbased prediction of volume of distribution. J. Pharm. Sci. 91, 129-156 (2002). (Pubitemid 34074473)
40. Berezhkovskiy, L.M. Volume of distribution at steady state for a linear pharmacokinetic system with peripheral elimination. J. Pharm. Sci. 93, 1628-1640 (2004). (Pubitemid 38725033)
41. Clements, J.A., Critchley, J.A. & Prescott, L.F. The role of sulphate conjugation in the metabolism and disposition of oral and intravenous paracetamol in man. Br. J. Clin. Pharmacol. 18, 481-485 (1984). (Pubitemid 14009940)
42. Prescott, L.F. Kinetics and metabolism of paracetamol and phenacetin. Br. J. Clin. Pharmacol. 10 (suppl. 2), S291-S298 (1980).
43. Mutlib, A.E., Goosen, T.C., Bauman, J.N., Williams, J.A., Kulkarni, S. & Kostrubsky, S. Kinetics of acetaminophen glucuronidation by UDP-glucuronosyltransferases 1A1, 1A6, 1A9 and 2B15. Potential implications in acetaminophen-induced hepatotoxicity. Chem. Res. Toxicol. 19, 701-709 (2006). (Pubitemid 43800987)
44. Laine, J.E., Auriola, S., Pasanen, M. & Juvonen, R.O. Acetaminophen bioactivation by human cytochrome P450 enzymes and animal microsomes. Xenobiotica. 39, 11-21 (2009).
45. Riches, Z., Bloomer, J., Patel, A., Nolan, A. & Coughtrie, M. Assessment of cryopreserved human hepatocytes as a model system to investigate sulfation and glucuronidation and to evaluate inhibitors of drug conjugation. Xenobiotica. 39, 374-381 (2009).
46. Vieira, M.L. et al. Predicting drug interaction potential with a physiologically based pharmacokinetic model: a case study of telithromycin, a time-dependent CYP3A inhibitor. Clin. Pharmacol. Ther. 91, 700-708 (2012).
47. Hardwick, R.N. et al. Altered UDP-glucuronosyltransferase and sulfotransferase expression and function during progressive stages of human nonalcoholic fatty liver disease. Drug Metab. Dispos. 41, 554-561 (2013).
48. Crewe, H.K., Barter, Z.E., Yeo, K.R. & Rostami-Hodjegan, A. Are there differences in the catalytic activity per unit enzyme of recombinantly expressed and human liver microsomal cytochrome P450 2C9? A systematic investigation into inter-system extrapolation factors. Biopharm. Drug Dispos. 32, 303-318 (2011).
49. Tan, C. & Graudins, A. Comparative pharmacokinetics of Panadol Extend and immediaterelease paracetamol in a simulated overdose model. Emerg. Med. Australas. 18, 398-403 (2006). (Pubitemid 43979284)